OYE Therapeutics Inc., a clinical-stage biotechnology company developing therapies for perioperative and emergency medicine, announced that the first subject has been dosed in its scientific bridging study evaluating OYE-101.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2026 Diabetes Prevention Awareness Center.